FDA safety alert: Efficacy concerns for a combination therapy in breast cancer treatment
Officials from the Food and Drug Administration (FDA) issued a safety alert on Sept. 8 about potential efficacy and safety concerns with Tecentriq in combination with Paclitaxel for breast cancer treatment.
A clinical trial that studied the use of atezolizumab (Tecentriq)and paclitaxel versus a placebo and Paclitaxel to treat metastatic triple-negative breast cancer found that the combination therapy did not significantly reduce the risk of cancer progression and death when compared with placebo and paclitaxel in the PD-L1-positive population.
In addition, interim overall survival results favored paclitaxel plus placebo over paclitaxel plus atezolizumab in both the PD-L1-positive population and the total population.
The FDA urged that health care professionals should not replace paclitaxel protein-bound with paclitaxel in clinical practice.
For more information, visit DrugTopics.com.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More
